This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-26 and is reviewed periodically as new material appears.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
=== Gene therapy === Gene therapy for hemoglobinopathies was first trialled in 2014 on a single patient with sickle cell disease (a fault in the beta globin gene), and followed by clinical trials in which a number of patients with either sickle cell or beta thalassemia were successfully treated. Gene therapies work by first harvesting the patient's HSCs, then using CRISPR gene editing to modify their DNA in the laboratory. In parallel with this, the person with thalassemia disease undergoes a myeloablation procedure (a form of chemotherapy) to destroy the remaining HSCs in their bone marrow. The laboratory treated cells are then infused back into the patient where they colonise the bone marrow and eventually commence production of healthy blood cells. There are fewer risks from this procedure than from HSCT, since the transplanted cells are autologous having originated from the patient herself/himself. There are two approved forms of gene therapy for beta thalassemia. Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia which adds a healthy beta-globin gene to the HSCs. It was approved for medical use in the United States in August 2022. The procedure involves collecting hematopoietic stem cells (HSCs) from the affected person's blood. In the laboratory, these HSCs then have a new gene for T87Q-globin (a modified beta-globin) introduced to them using a lentiviral vector.
=== Wet symptoms === Circulatory shock Diarrhea (feces which resemble more liquid than solid) Hemorrhage (bleeding) and sometimes bleeding diathesis (a person loses more blood than usual from an injury – for example, getting only a little cut, and losing a lot of blood) Petechiae (small red or purple spots) Swelling caused by edema The severity of symptoms varies with both individual immune competence and the type of virus. The "VHF syndrome" causes bleeding diathesis, capillary leak, and circulatory shock. It happens to most people who have Filoviridae infections (such as Ebola virus or Marburg virus), Crimean–Congo hemorrhagic fever (CCHF), or the South American hemorrhagic fevers (which are caused by Arenaviridae). VHF syndrome only happens to a small minority of people who have dengue fever or Rift Valley fever.
A mortar attack by insurgents killed six civilians and wounded 14 whereas two policemen were injured by sniper fire during the operation in Hangu, following which Pakistani forces took control of the area. Two children were killed and four were injured in crossfire during a skirmish in Bajaur District. On 7-8 May 2026, Pakistani forces conducted two operations in Dera Ismail Khan and Tank District, killing five militants. On 8 May 2026, eight civilians were injured in a quadcopter strike in Bannu District. A police constable was killed by militants after his abduction in Bajaur. On 9 May 2026, a car bomb exploded at a Pakistani checkpoint in Bannu, leaving at least 21 dead. Ittehad-ul-Mujahideen Pakistan, a Pakistani Taliban splinter group, claimed responsibility for the attack. On 10 May 2026, an Al-Qaeda affiliate was arrested by CTD in Pakpattan District. Pakistani forces killed seven militants including two key commanders, and destroyed militant infrastructure in a clearance operation in North Waziristan District. On 11 May 2026, a civilian was killed while foiling a suicide bombing in Attock District. On 12 May 2025, UNAMA stated that 372 civilians were killed and 397 had been wounded in Pakistani strikes on Afghanistan. On 13 May 2026, nine people including two traffic police personnel were killed and 33 injured in a VBIED attack by TTP in Lakki Marwat District, TTP militants also blew up a bridge in Bannu District. TTP militants captured a bank van and robbed PKR 80M. CM Khyber Pakhtunkhwa claimed that 80% of militants operating in the province were foreigners.
The clitoral body (also known as the shaft of the clitoris) is a portion behind the glans that contains the union of the corpora cavernosa, a pair of sponge-like regions of erectile tissue that hold most of the blood in the clitoris during erection. It is homologous to the penile shaft in the male. The two corpora forming the clitoral body are surrounded by thick fibro-elastic tunica albuginea, a sheath of connective tissue. These corpora are separated incompletely from each other in the midline by a fibrous pectiniform septum – a comblike band of connective tissue extending between the corpora cavernosa. The clitoral body is also connected to the pubic symphysis by the suspensory ligament. The body of the clitoris is a bent shape, which makes the clitoral angle or elbow. The angle divides the body into the ascending part (internal) near the pubic symphysis and the descending part (external), which can be seen and felt through the clitoral hood.
An isobaric tag for relative and absolute quantitation (iTRAQ) is a reagent for tandem mass spectrometry that is used to determine the amount of proteins from different sources in a single experiment. It uses stable isotope labeled molecules that can form a covalent bond with the N-terminus and side chain amines of proteins. The iTRAQ reagents are used to label peptides from different samples that are pooled and analyzed by liquid chromatography and tandem mass spectrometry. The fragmentation of the attached tag generates a low molecular mass reporter ion that can be used to relatively quantify the peptides and the proteins from which they originated.
Sources: en.wikipedia.org
The Paleolithic ( PAY-lee-oh-LITH-ik, PAL-ee-), or Old Stone Age, is a period in human prehistory distinguished by the original development of stone tools. It represents almost the entire period of human prehistoric technology, extending from the earliest known use of stone tools by hominins, c. 3.3 million years ago, to the end of the Pleistocene, c. 11,650 cal BP. The Paleolithic Age in Europe preceded the Mesolithic Age, although the date of the transition varies geographically by several thousand years. During the Paleolithic Age, hominins grouped together in small societies such as bands and subsisted by gathering plants, fishing, and hunting or scavenging wild animals. The Paleolithic Age is characterized by the use of knapped stone tools, although at the time humans also used wood and bone tools. Other organic commodities were adapted for use as tools, including leather and vegetable fibers; however, due to rapid decomposition, these have not survived to any great degree. About 50,000 years ago, a marked increase in the diversity of artifacts occurred. In Africa, bone artifacts and the first art appear in the archaeological record. The first evidence of human fishing is also noted, from artifacts in places such as Blombos Cave in South Africa. Archaeologists classify artifacts of the last 50,000 years into many different categories, such as projectile points, engraving tools, sharp knife blades, and drilling and piercing tools.
Tools were initially developed by hominids through observation and trial and error. Around 2 mya (million years ago), they learned to make the first stone tools by hammering flakes off a pebble, forming a sharp hand axe. This practice was refined 75 kya (thousand years ago) into pressure flaking, enabling much finer work. The discovery of fire was described by Charles Darwin as "possibly the greatest ever made by man". Archaeological, dietary, and social evidence point to "continuous [human] fire-use" at least 1.5 mya. Fire, fueled with wood and charcoal, allowed early humans to cook their food to increase its digestibility, improving its nutrient value and broadening the number of foods that could be eaten. The cooking hypothesis proposes that the ability to cook promoted an increase in hominid brain size, though some researchers find the evidence inconclusive. Archaeological evidence of hearths was dated to 790 kya; researchers believe this is likely to have intensified human socialization and may have contributed to the emergence of language. Other technological advances made during the Paleolithic era include clothing and shelter. No consensus exists on the approximate time of adoption of either technology, but archaeologists have found archaeological evidence of clothing 90-120 kya and shelter 450 kya. As the Paleolithic era progressed, dwellings became more sophisticated and more elaborate; as early as 380 kya, humans were constructing temporary wood huts.
Before the 1967 war, Christians comprised 12% of the total population of the Golan, which reached 150,000 people. While Druze formed the majority of the population. Christians were involved in small-scale economic and commercial activities, classified within the petite bourgeoisie, and most were educated, with many working in professions such as medicine, law, and engineering, while the Druze mainly worked in agriculture and on the land. The vast majority of Christians migrated with the rest of the population after Israel's occupation of the Golan, leaving only a few small Christian families. Of the four remaining Syrian Druze communities in the Israeli-occupied territories (on Israel's side of Mount Hermon and the Golan Heights), Majdal Shams is the largest, together with Ein Qiniyye, Mas'ade, and Buq'ata. As of 2017, there was one Greek Orthodox Christian family of five (the Nasrallah family) in Majdal Shams, and one Christian family of twelve (the Assaf family) in Ein Qiniyye. Only one Maronite church remains in Ein Qiniyye, along with remnants of two Melkite churches in Ein Qiniyye and one Orthodox church in Majdal Shams. The historic church of Banias remains closed despite restoration efforts. Relations between Christians and Druze in Majdal Shams and Ein Qiniyye are characterized by goodwill, peaceful coexistence, and mixing.
Adverse reaction Adverse event Adverse drug reaction Biosecurity Biosecurity in the United States Drug Efficacy Study Implementation Food and Drug Administration Modernization Act of 1997 FDA Food Safety Modernization Act of 2011 FDA Fast Track Development Program (for drugs) Food and Drug Administration Amendments Act of 2007 (e.g. drugs) Food and Drug Administration Safety and Innovation Act of 2012 (GAIN/QIDP etc.) Inverse benefit law Investigational Device Exemption (for use in clinical trials) Kefauver Harris Amendment 1962 – required "proof-of-efficacy" for drugs International:
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.